{
  "id": 20479424,
  "title": "Economic value of gonorrhea resistance testing in the United States: A multi-perspective modeling study",
  "url": "https://urgent.news/2026/11/17/economic-value-of-gonorrhea-resistance-testing-in-the-united-states-a",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-17T14:00:00.000Z",
  "source": {
    "name": "PLOS Medicine",
    "slug": "plos-medicine",
    "url": "https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005073"
  },
  "original_language": "en",
  "account": null,
  "summary": "by Brooke E. Nichols, Betsy Wonderly Trainor, Grace Hampson, Yonatan H. Grad, Jeffrey D. Klausner Background Rising antimicrobial resistance in Neisseria gonorrhoeae threatens the effectiveness of existing therapies. Ceftriaxone is the only recommended first-line (empiric) treatment for uncomplicated gonorrhea in the United States. Ciprofloxacin is no longer recommended for empiric use because of…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}